GoKawiil
Tech News
U.S. Customs and Border Protection announced it will suspend all personal importation of prescription medications beginning October 22, affecting Americans who order drugs from licensed Canadian pharmacies. The Canadian Pharmacy International Patients group is urging affected consumers to join its advocacy effort to preserve access to lower-cost medication.
Anthropic has quietly opened a physical biology lab in the San Francisco Bay Area, confirmed by its Head of Life Sciences Eric Kauderer-Abrams to Reuters. The lab supports both in-house experiments and outside collaborations, and is linked to but not limited to Claude Science, the drug discovery initiative Anthropic launched in June.
Researchers led by Stanford computer scientist James Zou built a system called Virtual Biotech, using up to 37,000 AI agents modeled like departments of a biotech company, overseen by a 'chief scientific officer' agent. After analyzing thousands of past clinical trials, the AI swarm flagged an immune-dampening protein as a target and, with human guidance, proposed a candidate treatment for lung cancer, detailed in a new Science paper.
Novo Nordisk, the Danish pharmaceutical company known for Ozempic and Wegovy, is rebranding itself as simply 'Novo' starting this week. The move shifts the company's public identity toward a shorter, more casual name as it markets directly to consumers rather than solely to healthcare providers.
Thatch, a startup that lets employers give workers a fixed healthcare budget to shop individual insurance plans, raised $108 million at a $1 billion valuation. That figure is more than double its $410 million valuation from 17 months ago, driven by roughly sevenfold growth in annual recurring revenue. The company uses an employer-funded model, recently rebranded CHOICE, that lets employees pick from various health, dental and vision plans and keep unused funds for other medical costs.
Novo Nordisk has entered a partnership with Anthropic to integrate the Claude AI model into its drug-discovery operations. The collaboration is designed to build targeted tools and workflows aimed at resolving persistent bottlenecks in pharmaceutical research.
Investors are reportedly re-entering rare-disease drug stocks after the departure of stricter FDA regulators under the Trump administration. The shift in agency leadership has reduced concerns about tougher approval hurdles that had previously discouraged investment in this biotech segment.
Executives from Nord Quantique and QuSecure discussed how quantum computing is moving from theoretical research toward real-world application, with heavy investment from governments and companies. They highlighted potential across drug discovery, materials science, finance and logistics, alongside the parallel risk quantum poses to current encryption standards.
Health benefits startup Thatch has raised $108 million in new funding at a $1 billion valuation, backed by existing investors including Andreessen Horowitz, General Catalyst, Index Ventures, and The General Partnership. The round comes just 17 months after Thatch was valued at $410 million, with CEO Chris Ellis saying annual recurring revenue grew roughly sevenfold in that span.
A group of drug companies trained an open-source AlphaFold 3 replica called OpenFold3 on more than 20,000 proprietary protein structures pooled from their private vaults. The resulting model outperformed versions trained only on public data or on any single firm's siloed dataset, according to an unpublished, non-peer-reviewed blog post.
Researchers at the University of Pennsylvania used AI to analyze over 400,000 Reddit posts from nearly 70,000 users discussing GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound. The analysis, published in Nature Health, surfaced patient-reported symptoms—particularly menstrual changes and temperature issues like chills and hot flashes—that appear underrepresented in clinical trials and regulatory data. The team stresses this doesn't prove the drugs cause these effects, but flags them as signals worth further study.
The Guardian gathered reader accounts describing how GLP-1 drugs like Wegovy, Ozempic and Mounjaro have reshaped family dynamics, with many users hiding their use out of shame. Several described feeling they had 'cheated' at weight loss, straining relationships with partners, children and friends who didn't know about the medication.